Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GliSODin for Melasma
NCT03878433Completed
- Sponsor
- Centre Hospitalier Universitaire de Nice
- Start
- Apr 2019
- Primary completion
- Jan 2020
- Countries
- 1
01
Overview
Randomised, double-blind trial in melasma (2 arms), sponsored by Centre Hospitalier Universitaire de Nice. Primary endpoint: Severity of melasma at 12 weeks. Started Apr 2019; status: completed.
02
Conditions
melasma
Beyond the preview
Go deeper on NCT03878433.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03878433.